ClinicalTrials.gg
RecruitingNCT06916507Updated Oct 2, 2026

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

An observational study in Parkinson's Disease, sponsored by AbbVie. Recruiting at 19 sites in Germany. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 2, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years to 67 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.

Planned enrollment
10th of 18
125 · median 131
Started
2025
with 3 others
Observational
18 of 44
5 open now
Registered
38th of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 10th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 38th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 67 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 125 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 20 sites in Germany.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • Foscarbidopa/Foslevodopa
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with advanced Parkinson's disease with time since the beginning of motor fluctuations \<= 5 years and the Hoehn and Yahr (H\&Y) stage \<= 3 in the on-medication condition treated with foslevodopa/foscarbidopa according to label in Germany

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease
  • Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label
  • Participant must be an adult male or female, 18-67 years of age
  • Time since beginning of motor fluctuations \<= 5 years
  • The Hoehn and Yahr (H\&Y) stage \<= 3
  • Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Previous Exposure to any device-aided therapy (DAT).
  • Any condition included in the section of the approved local LDp/CDp label.
  • Participants with (MMSE) score \< 24
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)

Groups and cohorts

  • Foslevodopa/Foscarbidopa

    Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in OFF Time (hours)

    The mean change from baseline to each scheduled visit in the number of hours spent in OFF time will be estimated using a mixed-effect model repeated-measures (MMRM).

    Time frame: Up to 6 months

07

Study locations

19 of 19 sites recruiting
  • Kliniken Schmieder - Allensbach /ID# 285402
    Allensbach, Baden-Wurttemberg 78476, Germany
    Recruiting
  • Universitaetsklinikum Heidelberg /ID# 274164
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
  • Universitaetsklinikum Tuebingen /ID# 275828
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
  • Praxis Prof. Kassubek/Prof. Riecker /ID# 274165
    Ulm, Baden-Wurttemberg 89073, Germany
    Recruiting
  • Parkinson-Klinik Ortenau GmbH&Co KG /ID# 274161
    Wolfach, Baden-Wurttemberg 77709, Germany
    Recruiting
  • Universitaetsklinikum Erlangen /ID# 280831
    Erlangen, Bavaria 91054, Germany
    Recruiting
  • Klinikum Ingolstadt /ID# 280573
    Ingolstadt, Bavaria 85049, Germany
    Recruiting
  • Klinikum der Universitaet Muenchen Grosshadern /ID# 274168
    Munich, Bavaria 81337, Germany
    Recruiting
  • Klinikum Ernst von Bergmann /ID# 274176
    Potsdam, Brandenburg 14467, Germany
    Recruiting
  • Universitaetskliniken Giessen und Marburg /ID# 274224
    Marburg, Hesse 35043, Germany
    Recruiting
  • Knappschaftskrankenhaus Bottrop /ID# 274284
    Bottrop, North Rhine-Westphalia 46242, Germany
    Recruiting
  • Cellitinnen-NTC Neurologisches Therapiecentrum /ID# 277865
    Cologne, North Rhine-Westphalia 50668, Germany
    Recruiting
  • Klinikum Lippe Detmold /ID# 279451
    Detmold, North Rhine-Westphalia 32756, Germany
    Recruiting
  • Klinikum Dortmund Klinikzentrum Mitte /ID# 280222
    Dortmund, North Rhine-Westphalia 44137, Germany
    Recruiting
  • Universitaetsklinikum Carl Gustav Carus Dresden /ID# 274167
    Dresden, Saxony 01307, Germany
    Recruiting
  • Krankenhaus Martha-Maria Halle-Dolau /ID# 274174
    Halle, Saxony-Anhalt 06120, Germany
    Recruiting
  • Praxis MD Oehlwein /ID# 274222
    Gera, Thuringia 07551, Germany
    Recruiting
  • Asklepios Fachklinikum Stadtroda /ID# 274162
    Stadtroda, Thuringia 07646, Germany
    Recruiting
  • Klinikum Bremen-Nord /ID# 275822
    Bremen, 28755, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 37 months is close to that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2027 → Jun 2028 and completion Sep 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
May 5, 2025
Primary completionEst.
Jun 2028was Sep 2027
CompletionEst.
Jun 2028was Sep 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 6, 2025→May 5, 2025
Oct 2, 2026
Primary completion
Sep 2027→Jun 2028
Oct 2, 2026
Study completion
Sep 2027→Jun 2028
Oct 2, 2026
Eligibility
Maximum age 64 Years→67 Years; 3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipant must be an adult male or female, 18-6467 years of age
  • EditedTime since beginning of motor fluctuations ≤ 3<= 5 years
  • EditedThe Hoehn and Yahr (H\&Y) stage <= 3 in the on-medication condition
Oct 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange From Baseline in OFF Time (hours)Up To 12 months → Up to 6 months
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date May 6, 2025→May 5, 2025
    Primary completion Sep 2027→Jun 2028
    Study completion Sep 2027→Jun 2028
    Eligibility Maximum age 64 Years→67 Years; 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipant must be an adult male or female, 18-6467 years of age
    • EditedTime since beginning of motor fluctuations ≤ 3<= 5 years
    • EditedThe Hoehn and Yahr (H\&Y) stage <= 3 in the on-medication condition
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange From Baseline in OFF Time (hours)Up To 12 months → Up to 6 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06916507
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
May 5, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Medical Information Germany
Contact
medinfo.germany@abbvie.com
49 611 1720 1520
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion